Cyprotex’ H1 income down, but revs soar on US expansion
UK preclinical contractor Cyprotex says H1 profits were hit by the loss of it biggest customer, but is upbeat on revenue growth and potential of in vitro toxicity testing business.
UK preclinical contractor Cyprotex says H1 profits were hit by the loss of it biggest customer, but is upbeat on revenue growth and potential of in vitro toxicity testing business.
The growth seen in the early-phase contract development sector earlier this year may have stalled as pharmaceutical industry sponsors continue to hold off on expensive toxicology studies, according to new analysis.
Drug delivery and pharmaceutical coating specialists SurModics are set to cut nine per cent of staff in a reshuffle of the business.
US chemicals maker Ashland says completion of ISP takeover means simplified supply chains for drug and cosmetics industry customers.
UPDATE
SCM Pharma has inked a commercial supply contract with Alliance for the sterile manufacturing of three of its products.
Irvine Scientific has begun shipping from the cell culture media plant it built to expand into Asia and give clients the security of a second source.